Filtered By:
Condition: Thrombosis
Drug: Activase

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 351 results found since Jan 2013.

Conversion From Intravenous Alteplase to Tenecteplase for Treatment of Acute Ischemic Stroke Across a Large Community Hospital Health System
CONCLUSION AND RELEVANCE: Conversion from alteplase to tenecteplase can be safely and effectively achieved at a large community hospital health system with differing levels of stroke certification. There were also additional cost savings and practical advantages including workflow benefits.PMID:36688289 | DOI:10.1177/10600280221149409
Source: The Annals of Pharmacotherapy - January 23, 2023 Category: Drugs & Pharmacology Authors: Erika Dittmar Thomas Wolfel Lourdes Menendez Jessilyn Pozo Maygret Ramirez Starlie C Belnap Felipe De Los Rios La Rosa Source Type: research

Effects of predictive nursing intervention on cognitive impairment and neurological function in ischemic stroke patients
ConclusionPredictive nursing intervention is beneficial to improve the effects of thrombolytic therapy in patients with ischemic stroke, which improves the neurological, cognitive and motor functions of patients, and reduces the occurrence of complications, suggesting an important clinical application value.
Source: Brain and Behavior - February 4, 2023 Category: Neurology Authors: Lianyu Xue, Jiangshan Deng, Lingyan Zhu, Feifei Shen, Jiewei Wei, Lihui Wang, Qinqin Chen, Lan Wang Tags: ORIGINAL ARTICLE Source Type: research

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
ConclusionsStandard-dose alteplase treatment reduced the risk of long-term recurrence of AIS after hospital discharge and the alteplase dose was not associated with the long-term risk of death from AIS.
Source: Neurology and Therapy - May 11, 2023 Category: Neurology Source Type: research

Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
Abstract Intravenous recombinant human tissue plasminogen activato (rtPA, formulated as alteplase) is the primary therapy for acute ischaemic stroke by breaking down a clot of an occluded vessel. There are several randomised controlled trials and observational studies that support the use of rtPA to improve functional outcome following acute ischaemic stroke. However, thrombolytic therapy with rtPA can be associated with a number of complications. Many of the rtPA-related complications result from its thrombolytic action including bleeding (intracerebral and systemic haemorrhage), reperfusion injury with oedema, a...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

2013 Round-Up Stroke: new horizons in treatment
Intra-arterial therapy (IAT) has been used for three decades to promote recanalisation after stroke. Whereas results of the Prolyse in Acute Cerebral Thromboembolism-II trial (PROACT-II) showed significant improvement in clinical outcome with intra-arterial fibrinolysis, the stroke specialty received some disturbing news in 2013. Results of the Interventional Management of Stroke-III (IMS-III), SYNTHESIS, and Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) studies failed to show an increased benefit for IAT compared with intravenous alteplase (t-PA) or as an adjunctive approach to intravenous alteplase.
Source: Lancet Neurology - December 9, 2013 Category: Neurology Authors: Amrou Sarraj, James C Grotta Tags: 2013 Round-Up Source Type: research

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke
Background: Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking. The Norwegian Tenecteplase Stroke Trial (NOR-TEST) aims to compare efficacy and safety of tenecteplase vs. alteplase. Methods: NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial designed to establish superiority of tenectepl...
Source: BMC Neurology - May 15, 2014 Category: Neurology Authors: Nicola LogalloChristopher KvistadAliona NacuHalvor NaessUlrike Waje-AndreassenJörg AsmussAnne Hege AamodtChristian LundMartin KurzOle Morten RønningRolf SalvesenTitto IdiculaLars Thomassen Source Type: research

To determine the impact of serum albumin levels on admission with the outcomes in patients receiving IV-t-PA (alteplase) for treatment of acute ischemic stroke. (P5.134)
Conclusion: Among ischemic stroke patients treated with thrombolysis admission hypoalbuminemia was not a predictor of poor outcome. This will need to be validated in larger studies.Disclosure: Dr. Limaye has nothing to disclose. Dr. Lahoti has nothing to disclose. Dr. Hinduja has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Limaye, K., Lahoti, S., Hinduja, A. Tags: Cerebrovascular Disease and Interventional Neurology: Biomarkers and Emerging Science Source Type: research

Quality of Life After Off-Label Thrombolysis for Ischemic Stroke in Elderly Patients
Conclusion QOL after intravenous thrombolysis in the elderly population was comparable to that of younger subjects. Despite its small sample size, this study showed promising results in favor of intravenous thrombolysis in the elderly population and highlighted the importance of systematic screening for post-stroke cognitive impairment, particularly in this population.
Source: Drugs and Aging - October 7, 2015 Category: Geriatrics Source Type: research